These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
5. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
6. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694 [TBL] [Abstract][Full Text] [Related]
7. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease. Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436 [TBL] [Abstract][Full Text] [Related]
8. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113 [TBL] [Abstract][Full Text] [Related]
14. Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status? Lee HL; Seok HY; Ryu HW; Cho EB; Kim BC; Kim BJ; Min JH; Seok JM; Shin HY; Kang SY; Kwon OH; Lee SS; Oh J; Sohn EH; Huh SY; Cho JY; Seong JY; Kim BJ Mult Scler; 2020 Nov; 26(13):1700-1707. PubMed ID: 31680620 [TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Gospe SM; Chen JJ; Bhatti MT Eye (Lond); 2021 Mar; 35(3):753-768. PubMed ID: 33323985 [TBL] [Abstract][Full Text] [Related]
16. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis. Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112 [TBL] [Abstract][Full Text] [Related]
17. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature. Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992 [TBL] [Abstract][Full Text] [Related]
18. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults. Duan Z; Feng J J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder. Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114 [TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]